Anxiety and Depression in Adolescent PCOS

NCT07127458 | Completed

• 1 other identifier: A-PCOS-1
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in adolescent females, often accompanied by psychological symptoms such as anxiety and depression. These conditions are frequently underdiagnosed and untreated. This study aims to determine the prevalence of anxiety and depression in adolescents with PCOS and to assess changes following oral contraceptive use.

Conditions

PCOS (Polycystic Ovary Syndrome)

Keywords

Polycystic Ovary Syndrome (PCOS); Adolescents; Anxiety and Depression

Outcome Measures

Primary Outcomes (1)

• Change in Beck Depression Inventory

  Change in Beck Depression Inventory Score After 6 Months of Oral Contraceptive Use

  6 Months

Study Arms (1)

Adolescents with Polycystic Ovary Syndrome

EXPERIMENTAL

Adolescent patients with PCOS will be identified, and the prevalence of anxiety and depression will be assessed. Oral contraceptive therapy will be initiated, and patients will be re-evaluated after 6 months.

Drug: Adolescent PCOS group receiving oral contraceptives

Interventions

Adolescent PCOS group receiving oral contraceptives DRUG

Participants diagnosed with polycystic ovary syndrome (PCOS) during adolescence will receive a combined oral contraceptive (ethinylestradiol 30 µg + drospirenone 3 mg) once daily for six consecutive months. The intervention aims to regulate menstrual cycles, reduce hyperandrogenic symptoms, and evaluate changes in anxiety and depression scores over time.

Adolescents with Polycystic Ovary Syndrome

Eligibility Criteria

• Age: 15 Years - 19 Years
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Age between 15 and 19 years
• Diagnosis of adolescent polycystic ovary syndrome (PCOS)

You may not qualify if:

• Severe reading or comprehension difficulties
• Severe hearing impairment
• Current use of hormone therapy
• Presence of a virilizing tumor
• Major psychiatric disorders such as schizophrenia, bipolar disorder, or dissociative disorder

Sponsors & Collaborators

• Ege University: lead

Study Sites (1)

Izmir Bakircay University

Izmir, 35665, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Polycystic Ovary Syndrome; Anxiety Disorders; Depression

Condition Hierarchy (Ancestors)

Ovarian Cysts; Cysts; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Gonadal Disorders; Endocrine System Diseases; Mental Disorders; Behavioral Symptoms; Behavior

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: August 11, 2025
• First Posted: August 17, 2025
• Study Start: August 17, 2025
• Primary Completion: March 17, 2026
• Study Completion: March 17, 2026
• Last Updated: March 25, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will share

Locations

TU (1)